ProCE Banner Activity

Investigational PPAR-delta Agonist for PBC Treatment and Race-Based Considerations for PBC Diagnosis: Conference Coverage of AASLD

Conference Coverage
Podcast Episodes

Listen as Stuart C. Gordon, MD, FAASLD, discusses exciting new PBC data from AASLD 2023, including a late-breaking study of a PPAR-delta agonist and a study that explored racial differences as they relate to the presentation and diagnosis of PBC.

Released: December 07, 2023

Begin Activity

Share

Faculty

Stuart Gordon

Stuart Gordon, MD, FAASLD

Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from CymaBay Therapeutics.

CymaBay Therapeutics

Disclosure

Primary Author

Stuart Gordon, MD, FAASLD

Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Stuart C. Gordon, MD, FAASLD: researcher (paid to institution): AbbVie, Arbutus, CymaBay, DURECT, Eiger, Enanta, Gilead Sciences, GlaxoSmithKline, Hightide, Intercept, Ipsen, Mirum, Pliant; consultant: AbbVie, CymaBay, Gilead, GlaxsoSmithKline, Ipsen.